Illumina, Inc. $ILMN Stock Holdings Lessened by National Pension Service

Key Points

• The National Pension Service reduced its holdings in Illumina, Inc. by 87.3%, now owning 33,743 shares valued at $2.68 million after selling 231,380 shares during Q1.
• Institutional investors continue to have significant stakes in Illumina, with 89.42% of the company's stock owned by institutions and notable increases from firms like Capital World Investors and Vanguard Group.
• Analysts' ratings for Illumina are mixed, with recent price targets ranging from a low of $94 to a high of $126, reflecting varying outlooks on the company's performance.

National Pension Service trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 87.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,743 shares of the life sciences company's stock after selling 231,380 shares during the period. National Pension Service's holdings in Illumina were worth $2,677,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of ILMN. Capital World Investors lifted its stake in shares of Illumina by 408.6% in the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after acquiring an additional 14,481,232 shares during the period. Brown Advisory Inc. lifted its holdings in shares of Illumina by 54,220.9% in the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock valued at $255,586,000 after buying an additional 1,909,118 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Illumina by 2,057.5% in the first quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock valued at $73,174,000 after buying an additional 879,533 shares during the period. Vanguard Group Inc. lifted its holdings in Illumina by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock valued at $1,298,928,000 after acquiring an additional 558,243 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its holdings in Illumina by 2,292.9% in the 1st quarter. Pacer Advisors Inc. now owns 565,680 shares of the life sciences company's stock valued at $44,881,000 after acquiring an additional 542,040 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Wall Street Zen downgraded shares of Illumina from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Barclays increased their target price on shares of Illumina from $85.00 to $90.00 and gave the company an "underweight" rating in a research note on Friday, August 1st. Morgan Stanley increased their price objective on Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a research report on Monday, August 4th. Stephens set a $110.00 price objective on Illumina and gave the company an "overweight" rating in a research report on Monday, August 4th. Finally, Robert W. Baird increased their price objective on Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a research report on Monday, July 28th. Seven research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $124.58.

Illumina Trading Down 0.4%

Shares of NASDAQ:ILMN traded down $0.3990 during mid-day trading on Thursday, hitting $100.4010. The stock had a trading volume of 498,247 shares, compared to its average volume of 2,334,934. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The company has a market cap of $15.43 billion, a PE ratio of 12.71, a P/E/G ratio of 2.28 and a beta of 1.37. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The company's 50 day moving average is $97.66 and its 200-day moving average is $89.50.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company's revenue for the quarter was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.